Related references
Note: Only part of the references are listed.PROTAC cell permeability and oral bioavailability: a journey into uncharted territory
Vasanthanathan Poongavanam et al.
FUTURE MEDICINAL CHEMISTRY (2022)
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
W. Clay Gustafson et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
John H Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Victoria Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts
Vania Vidimar et al.
MOLECULAR CANCER THERAPEUTICS (2022)
KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta et al.
NATURE CHEMICAL BIOLOGY (2022)
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang et al.
CANCER DISCOVERY (2022)
First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
Shubham Pant et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
The Rise of Molecular Glues
Stuart L. Schreiber
CELL (2021)
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
Joshua K. Sabari et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
M. Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
Amin H. Nassar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report
Qinghan Liu et al.
TUMORI JOURNAL (2021)
Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States
Shuhui Lim et al.
ACS CENTRAL SCIENCE (2021)
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
Chuanchuan Li et al.
SCIENCE (2021)
KRAS drives immune evasion in a genetic model of pancreatic cancer
Irene Ischenko et al.
NATURE COMMUNICATIONS (2021)
Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
Adelina Plangger et al.
TRANSLATIONAL ONCOLOGY (2021)
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
Teklab Gebregiworgis et al.
NATURE COMMUNICATIONS (2021)
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
Febe van Maldegem et al.
NATURE COMMUNICATIONS (2021)
Bispecific antibodies targeting mutant RAS neoantigens
Jacqueline Douglass et al.
SCIENCE IMMUNOLOGY (2021)
99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
G.J. Riely et al.
Journal of Thoracic Oncology (2021)
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
ES28.04 Emerging Mechanisms to Target KRAS Directly
M. Nagasaka
Journal of Thoracic Oncology (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
J. Weiss et al.
ANNALS OF ONCOLOGY (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)
David Gandara et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
Suresh Ramalingam et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Sarah Greene et al.
CLINICAL CANCER RESEARCH (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Timothy H. Tran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Keisuke Yamamoto et al.
NATURE (2020)
Guidelines and definitions for research on epithelial-mesenchymal transition
Jing Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer
Yuta Adachi et al.
CLINICAL CANCER RESEARCH (2020)
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Nicolas Bery et al.
NATURE COMMUNICATIONS (2020)
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
Maria Paz Zafra et al.
CANCER DISCOVERY (2020)
KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
Tatu Pantsar
SCIENTIFIC REPORTS (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Ziyang Zhang et al.
ACS CENTRAL SCIENCE (2020)
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Harold J. Burstein
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer
Wells S. Brown et al.
CELL REPORTS MEDICINE (2020)
BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
Daniel Gerlach et al.
CANCER RESEARCH (2020)
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
Rakshamani Tripathi et al.
NATURE COMMUNICATIONS (2020)
The current understanding of KRAS protein structure and dynamics
Tatu Pantsar
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C. Hillig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment
A. Tirella et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
Aditi Mehta et al.
PHARMACEUTICAL RESEARCH (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
RAS: Striking at the Core of the Oncogenic Circuitry
Ryan C. Gimple et al.
FRONTIERS IN ONCOLOGY (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
Bifunctional Small-Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins
Ziyang Zhang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Pharmacological targeting of RAS: Recent success with direct inhibitors
John P. O'Bryan
PHARMACOLOGICAL RESEARCH (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Exceptionally high-affinity Ras binders that remodel its effector domain
John H. McGee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
A Convergence-Based Framework for Cancer Drug Resistance
David J. Konieczkowski et al.
CANCER CELL (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Mylene Tajan et al.
ENDOCRINE REVIEWS (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S. Wong et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Vincent L. Cannataro et al.
ONCOGENE (2018)
Afatinib restrains K-RAS-driven lung tumorigenesis
Herwig P. Moll et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Elisa Caiola et al.
SCIENTIFIC REPORTS (2018)
Targeting the MAPK Pathway in RAS Mutant Cancers
Sarah G. Hymowitz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Shunsuke Kitajima et al.
CANCER CELL (2018)
Regulatory mechanisms of PD-L1 expression in cancer cells
Yongyu Shi
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
The functional diversity of Aurora kinases: a comprehensive review
Estelle Willems et al.
CELL DIVISION (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects
Christian W. Johnson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar et al.
NATURE (2017)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Rodrigo Romero et al.
NATURE MEDICINE (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg et al.
TARGETED ONCOLOGY (2017)
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
Satoshi Sogabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer
Ahmed S. K. Al-Khafaji et al.
ONCOLOGY LETTERS (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Leanne G. Ahronian et al.
GENOME MEDICINE (2017)
Deconstruction of the Ras switching cycle through saturation mutagenesis
Pradeep Bandaru et al.
ELIFE (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Role of SHP2 in hematopoiesis and leukemogenesis
Ruchi Pandey et al.
CURRENT OPINION IN HEMATOLOGY (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Sticking It to Cancer with Molecular Glue for SHP2
Hao Ran et al.
CANCER CELL (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J. E. Grilley-Olson et al.
INVESTIGATIONAL NEW DRUGS (2016)
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Edmilson Ozorio dos Santos et al.
MOLECULAR CANCER (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Margaret Soucheray et al.
CANCER RESEARCH (2015)
Functions of Shp2 in cancer
Jie Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition
Pavel A. Levin et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site
Mohammad T. Mazhab-Jafari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
Sang Min Lim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Diletta Di Mitri et al.
NATURE (2014)
Integrated RAS signaling defined by parallel NMR detection of effectors and regulators
Matthew J. Smith et al.
NATURE CHEMICAL BIOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis
Hiroshi Katoh et al.
CANCER CELL (2013)
Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
Winfried H. Alsdorf et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
The genetics and biology of KRAS in lung cancer
Peter M. K. Westcott et al.
CHINESE JOURNAL OF CANCER (2013)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Swarnali Acharyya et al.
CELL (2012)
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Thomas Jamieson et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
Philip C. De Witt Hamer et al.
CLINICAL CANCER RESEARCH (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer
Toshiaki Watanabe et al.
DISEASES OF THE COLON & RECTUM (2011)
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2011)
Germline KRAS Mutations Cause Aberrant Biochemical and Physical Properties Leading to Developmental Disorders
Lothar Gremer et al.
HUMAN MUTATION (2011)
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Hideaki Ijichi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
Leina Sun et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
Katharina Schmid et al.
CLINICAL CANCER RESEARCH (2009)
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
Li Yang et al.
CANCER CELL (2008)
BRAF V600E disrupts AZD6244-Induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins
Bret B. Friday et al.
CANCER RESEARCH (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke:: Distinct patterns in never, former, and current smokers
F Le Calvez et al.
CANCER RESEARCH (2005)
Recognizing and defining true Ras binding domains 1:: Biochemical analysis
S Wohlgemuth et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
BG Neel et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens
KY See et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
Share Paper
